Business

The Food and Drug Administration recently gave its approval for Moderna’s vaccine for respiratory syncytial virus (RSV) specifically targeting adults aged 60 and above. This marks a significant milestone for Moderna as it introduces its second product into the U.S. market. The approval comes at a critical time for the company, facing decreasing demand for
American Eagle reported a significant improvement in profitability, with earnings per share coming in at 34 cents, exceeding Wall Street expectations of 28 cents. However, the company’s fiscal first-quarter sales fell short of what was anticipated, with revenue reaching $1.14 billion versus the expected $1.15 billion. As a result, shares of American Eagle dropped by